These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

388 related articles for article (PubMed ID: 18720264)

  • 1. Multiple sclerosis following etanercept treatment for ankylosing spondylitis.
    Pfueller CF; Seipelt E; Zipp F; Paul F
    Scand J Rheumatol; 2008; 37(5):397-9. PubMed ID: 18720264
    [No Abstract]   [Full Text] [Related]  

  • 2. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha.
    Gorman JD; Sack KE; Davis JC
    N Engl J Med; 2002 May; 346(18):1349-56. PubMed ID: 11986408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New-onset psoriasis associated with etanercept therapy.
    Chen LA; Su LH; Chang YJ; Hsu YL; Tsai TH
    J Dermatol; 2010 Apr; 37(4):378-80. PubMed ID: 20507411
    [No Abstract]   [Full Text] [Related]  

  • 4. Switching from infliximab to once-weekly administration of 50 mg etanercept in resistant or intolerant patients with ankylosing spondylitis: results of a fifty-four-week study.
    Cantini F; Niccoli L; Benucci M; Chindamo D; Nannini C; Olivieri I; Padula A; Salvarani C
    Arthritis Rheum; 2006 Oct; 55(5):812-6. PubMed ID: 17013842
    [No Abstract]   [Full Text] [Related]  

  • 5. Uveitis and tumour necrosis factor blockade in ankylosing spondylitis.
    Coates LC; McGonagle DG; Bennett AN; Emery P; Marzo-Ortega H
    Ann Rheum Dis; 2008 May; 67(5):729-30. PubMed ID: 18408116
    [No Abstract]   [Full Text] [Related]  

  • 6. BSR guidelines for prescribing TNF-alpha blockers in adults with ankylosing spondylitis. Report of a working party of the British Society for Rheumatology.
    Keat A; Barkham N; Bhalla A; Gaffney K; Marzo-Ortega H; Paul S; Rogers F; Somerville M; Sturrock R; Wordsworth P;
    Rheumatology (Oxford); 2005 Jul; 44(7):939-47. PubMed ID: 15901904
    [No Abstract]   [Full Text] [Related]  

  • 7. Emergence of Crohn's disease during treatment with the anti-tumor necrosis factor agent etanercept for ankylosing spondylitis: possible mechanisms of action.
    Haraoui B; Krelenbaum M
    Semin Arthritis Rheum; 2009 Dec; 39(3):176-81. PubMed ID: 18706681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute myelogenous leukaemia following etanercept therapy.
    Bakland G; Nossent H
    Rheumatology (Oxford); 2003 Jul; 42(7):900-1. PubMed ID: 12826706
    [No Abstract]   [Full Text] [Related]  

  • 9. Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis.
    Brandt J; Listing J; Haibel H; Sörensen H; Schwebig A; Rudwaleit M; Sieper J; Braun J
    Rheumatology (Oxford); 2005 Mar; 44(3):342-8. PubMed ID: 15561737
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Etanercept in adult patients with early onset ankylosing spondylitis.
    Inman RD; Clegg DO; Davis JC; Whitmore JB; Solinger A
    J Rheumatol; 2006 Aug; 33(8):1634-6. PubMed ID: 16881118
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of sarcoidosis during etanercept therapy.
    González-López MA; Blanco R; González-Vela MC; Fernández-Llaca H; Rodríguez-Valverde V
    Arthritis Rheum; 2006 Oct; 55(5):817-20. PubMed ID: 17013853
    [No Abstract]   [Full Text] [Related]  

  • 12. Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis.
    Davis JC; van der Heijde DM; Braun J; Dougados M; Clegg DO; Kivitz AJ; Fleischmann RM; Inman RD; Ni L; Lin SL; Tsuji WH
    Ann Rheum Dis; 2008 Mar; 67(3):346-52. PubMed ID: 17967833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-TNF-alpha therapy for ankylosing spondylitis--a specific or nonspecific treatment?
    Dayer JM; Krane SM
    N Engl J Med; 2002 May; 346(18):1399-400. PubMed ID: 11986415
    [No Abstract]   [Full Text] [Related]  

  • 14. Treatment of rheumatic inflammatory disease in 25 patients with secondary amyloidosis using tumor necrosis factor alpha antagonists.
    Fernández-Nebro A; Tomero E; Ortiz-Santamaría V; Castro MC; Olivé A; de Haro M; Portales RG; González-Mari MV; Laffón A; García-Vicuña R
    Am J Med; 2005 May; 118(5):552-6. PubMed ID: 15866260
    [No Abstract]   [Full Text] [Related]  

  • 15. Aortitis during etanercept therapy for ankylosing spondylitis: finding the culprit.
    Verhoeven F; Bossert M; Lohse-Walliser A; Balblanc JC
    Joint Bone Spine; 2012 Oct; 79(5):524-6. PubMed ID: 22575065
    [No Abstract]   [Full Text] [Related]  

  • 16. Rapid remission of treatment-resistant ankylosing spondylitis with etanercept--a drug for refractory ankylosing spondylitis?
    Barthel HR
    Arthritis Rheum; 2001 Aug; 45(4):404. PubMed ID: 11501730
    [No Abstract]   [Full Text] [Related]  

  • 17. Etanercept induced multiple sclerosis and transverse myelitis.
    Al Saieg N; Luzar MJ
    J Rheumatol; 2006 Jun; 33(6):1202-4. PubMed ID: 16755671
    [No Abstract]   [Full Text] [Related]  

  • 18. Outcome of patients with active ankylosing spondylitis after two years of therapy with etanercept: clinical and magnetic resonance imaging data.
    Baraliakos X; Brandt J; Listing J; Haibel H; Sörensen H; Rudwaleit M; Sieper J; Braun J
    Arthritis Rheum; 2005 Dec; 53(6):856-63. PubMed ID: 16342093
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Etanercept: new indication. For ankylosing spondylitis: another option.
    Prescrire Int; 2005 Jun; 14(77):92-3. PubMed ID: 15981387
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical efficacy and safety of etanercept versus sulfasalazine in patients with ankylosing spondylitis: a randomized, double-blind trial.
    Braun J; van der Horst-Bruinsma IE; Huang F; Burgos-Vargas R; Vlahos B; Koenig AS; Freundlich B
    Arthritis Rheum; 2011 Jun; 63(6):1543-51. PubMed ID: 21630245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.